Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns
NCT04839523 · View on ClinicalTrials.gov ↗
Study Summary
This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to the Subject's last clinical follow-up visit. Sixty-eight (68) eligible subjects, with moderate to high exuding partial-thickness burns, will be selected for treatment with either Exufiber Ag+ silver-coated gelling dressing, or Exufiber gelling dressing. The study will last 5 weeks, with a requirement of 5 study visits in total, including dressing changes at each study visit.
Conditions Studied
Interventions
- DEVICE Exufiber
- DEVICE Exufiber Ag+
Study Locations (6)
Arizona
- Arizona Burn Center, Valleywise Health — Phoenix
California
- Keck Medical Center of USC — Los Angeles
District of Columbia
- MedStar Health Research Institute — Washington D.C.
Florida
- University of South Florida-Tampa General Hospital — Tampa
Massachusetts
- Massachusetts General Hospital — Boston
Pennsylvania
- Drexel Univerisity — Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-03-10 |
| Est. Completion | 2024-12-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04839523
The ClinicalTrials.gov registry entry for NCT04839523 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Molnlycke Health Care AB, which has 41 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Partial-thickness Burn appearing as the primary indexed condition, and to 2 interventions — of which Exufiber is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04839523 reports 6 study locations spanning 6 distinct geographic areas — top geographies include Arizona, California, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04839523 about?
NCT04839523 is a clinical study titled "Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns". This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to...
What is the current status of trial NCT04839523?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 44 participants. The study started on 2021-03-10. Estimated completion is 2024-12-31.
What conditions does trial NCT04839523 study?
This clinical trial studies the following conditions: Partial-thickness Burn. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04839523?
The interventions under investigation include: Exufiber (DEVICE), Exufiber Ag+ (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04839523?
This trial is sponsored by Molnlycke Health Care AB, which has 41 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04839523 being conducted?
This trial has 6 study locations across Arizona, California, District of Columbia, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.